Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of ocrelizumab access and physical function outcomes in multiple sclerosis
2023-507633-21-01Phase 3Authorised
- Sponsor
- Roche
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoints: Change from baseline to end of study in PROMIS/Neuro-QoL Physical Function Measure for Multiple Sclerosis 15a and Number of eligible participants receiving access to ocrelizumab. Planned start Dec 2024; status: authorised.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-507633-21-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507633-21-01.